Eli Lilly's Weight Loss Drug Combo Tops 23% Body Weight Reduction in Trial
The combination of tirzepatide and eloralintide achieved significant weight loss in mid-stage trials, prompting plans for Phase 3 studies despite tolerability concerns.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
First reported by Quartz, 2h 04m ahead of the next publisher · who breaks stories first
This story has stopped developing; this page is its permanent record. More from that day
The story so far
5 publishers have covered this in 9 articles since 30 Sept 2026. Quartz published first, on 30 September at 12:10 UTC; STAT followed 2h 04m later. The most recent article, from CNBC, appeared on 2 October at 15:20 UTC.
Outlets reporting it: CNBC (major outlet), Quartz, STAT, MarketWatch, MedPageToday.com - medical news for physicians.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- QuartzEli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial
- QuartzDas experimentelle Gewichtsverlust-Medikament von Eli Lilly reduzierte das Körpergewicht in einer Diabetes-Studie um 21 %.
- STATSTAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
- CNBCEli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- MarketWatchAdding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
- QuartzEli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
- QuartzEli Lillys Gewichtsverlust-Medikamenten-Kombination reduziert das Körpergewicht um 23 % und übertrifft damit seinen eigenen Blockbuster.
- MedPageToday.com - medical news for physiciansStriking Weight Loss Seen With Combo Drug in Diabetes Trial
- CNBCWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s CNBC ·
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial CNBC ·
- Striking Weight Loss Seen With Combo Drug in Diabetes Trial MedPageToday.com - medical news for physicians
- Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster Quartz
- Eli Lillys Gewichtsverlust-Medikamenten-Kombination reduziert das Körpergewicht um 23 % und übertrifft damit seinen eigenen Blockbuster. Quartz
- Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects. MarketWatch
Show 3 more sources
- STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial STAT
- Eli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial Quartz
- Das experimentelle Gewichtsverlust-Medikament von Eli Lilly reduzierte das Körpergewicht in einer Diabetes-Studie um 21 %. Quartz
In this story
- Eli Lilly
- tirzepatide
- eloralintide